MITAC-COMPUTING
27.5.2019 04:02:06 CEST | Business Wire | Press release
TYAN® , an industry-leading server platform design manufacturer and a subsidiary of MiTAC Computing Technology Corporation, will be exhibiting a full line of HPC, storage and cloud computing server platforms that are optimized for HPC, enterprise and datacenter markets at Computex 2019 from May 28th to June 1st , Booth # L0631a in Taipei, Taiwan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190526005002/en/
“The increasingly growing demand for AI is transforming the data center and is resulting in a tremendous amount of data being pulled into big data platforms at massive scale,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. “TYAN’s leading portfolio of HPC, storage and cloud server platforms are based on the 2nd gen Intel® Xeon® Scalable processors and are designed to help enterprises and data center service providers capture, process, and analyze big data faster and at a more powerful rate than ever before.”
2nd Gen Intel Xeon Scalable Processors Empower TYAN HPC and Storage Platforms to Deliver Leading Performance
TYAN’s HPC and storage server platforms are built on the 2nd gen Intel Xeon Scalable processors with accompanying new innovations of Intel® Deep Learning Boost technology and Intel® Optane™ DC persistent memory that enable faster machine learning application execution and accelerated workload processing and service delivery. The new Thunder HX FT83-B7119 is an AI-optimized platform and is ideal for AI training and inference applications. The system supports for up to 3TB of memory and 12 hot-swappable 3.5” drives in a 4U enclosure.
The Thunder SX FA100-B7118 is TYAN’s flagship storage server supporting dual-socket 2nd gen Intel Xeon Scalable processors and 100 3.5” drives in a 4U rackmount form factor. The platform is designed for both cold storage and large-scale object storage applications such as Lustre. TYAN’s Thunder SX TN76-B7102 is 2U dual-socket 2nd gen Intel Xeon Scalable processor-based storage platform. With support for up to 24 DDR4 DIMM slots and maximum expansion up to 8 standard PCIe slots, the TN76-B7102 can fully address the high memory capacity required by data virtualization and in-memory databases.
For the high-performance storage segment, the Thunder SX GT62H-B7106 is a 1U server platform with support hot-swap all-flash drives. The GT62H-B7106 features dual-socket 2nd gen Intel Xeon Scalable processors, 16 DIMM slots, two low profile PCIe x16 slots, and 10 U.2 NVMe drive bays. This platform offers maximum storage performance and large memory capacity and is ideal for edge server applications.
The new Thunder SX GT90-B7113 features support for dual 2nd gen Intel Xeon Scalable processors, 12 hot-swap 3.5” drives mounted to a service drawer and 4 hot-swap NVMe U.2 drive bays in a 35” deep 1U chassis. The platform perfectly matches CSP server-based software-defined storage applications by allowing serviceability and density within the same server.
Intel ® Xeon ® D-2100 and Intel ® Xeon ® E-2100 Processor-based Platforms to Maximize Compute Performance and Efficiency for Cloud and Storage
Powered by the Intel Xeon D-2100 processors, TYAN Thunder SX TE70-B5546 and Thunder SX TE73-B5546 platforms are optimized to deliver rich features of low-power, high-density and high-availability. These two systems are both in 2U dual-node form factor with dual-controller, dual-path redundant design for high availability requirement and support dual-port SAS/NVMe storage functions for today’s high available data-intensive storage environments. TE70-B5546 supports up to 24 2.5” dual-port SAS 12Gb/s drive bays and 4 of bays supports dual-port NVMe U.2; TE73-B5546 supports up to 12 3.5” dual-port SAS 12Gb/s drive bays and 4 of bays supports dual-port NVMe U.2.
Moreover, taking full advantage of Intel Xeon E-2100 processors, TYAN offers increased reliability, security, performance, and affordability for its entry server lineup. TYAN’s Thunder CX GT24E-B5556 is a 1U single-socket Intel Xeon E-2100 processor-based edge cloud server. With support for up to 4 DDR4 DIMM slots, 3 PCIe slots, and dual 10GBase-T Ethernet ports, the platform is optimized for cost-effective cloud gaming applications. The Thunder CX GX38-B5550 is 1U single-socket Intel Xeon E-2100 processor-based compact sever with shallow chassis and support for 2 3.5” internal SATA drive bays for IoT applications.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190526005002/en/
Contact:
MiTAC Computing Technology Corporation/ TYAN Business Unit Fenny Chen fenny.chen@tyan.com.tw
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom